A summary of the new GINA strategy: a roadmap to asthma control

Helen K Reddel, Eric D Bateman, Allan Becker, Louis-Philippe Boulet, Alvaro A Cruz, Jeffrey M Drazen, Tari Haahtela, Suzanne S Hurd, Hiromasa Inoue, Johan C de Jongste, Robert F Lemanske Jr, Mark L Levy, Paul M O'Byrne, Pierluigi Paggiaro, Soren E Pedersen, Emilio Pizzichini, Manuel Soto-Quiroz, Stanley J Szefler, Gary W K Wong, J Mark FitzGerald, Helen K Reddel, Eric D Bateman, Allan Becker, Louis-Philippe Boulet, Alvaro A Cruz, Jeffrey M Drazen, Tari Haahtela, Suzanne S Hurd, Hiromasa Inoue, Johan C de Jongste, Robert F Lemanske Jr, Mark L Levy, Paul M O'Byrne, Pierluigi Paggiaro, Soren E Pedersen, Emilio Pizzichini, Manuel Soto-Quiroz, Stanley J Szefler, Gary W K Wong, J Mark FitzGerald

Abstract

Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. However, uptake of existing guidelines is poor. A major revision of the GINA report was published in 2014, and updated in 2015, reflecting an evolving understanding of heterogeneous airways disease, a broader evidence base, increasing interest in targeted treatment, and evidence about effective implementation approaches. During development of the report, the clinical utility of recommendations and strategies for their practical implementation were considered in parallel with the scientific evidence.This article provides a summary of key changes in the GINA report, and their rationale. The changes include a revised asthma definition; tools for assessing symptom control and risk factors for adverse outcomes; expanded indications for inhaled corticosteroid therapy; a framework for targeted treatment based on phenotype, modifiable risk factors, patient preference, and practical issues; optimisation of medication effectiveness by addressing inhaler technique and adherence; revised recommendations about written asthma action plans; diagnosis and initial treatment of the asthma-chronic obstructive pulmonary disease overlap syndrome; diagnosis in wheezing pre-school children; and updated strategies for adaptation and implementation of GINA recommendations.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Copyright ©ERS 2015.

Figures

FIGURE 1
FIGURE 1
The Global Initiative for Asthma (GINA) control-based cycle of asthma care. This figure highlights key priorities in management of asthma in the GINA global asthma strategy. Further details can be found in boxes 3–3 and 3–5 in the full GINA 2015 report (“Global Strategy for Asthma Management and Prevention”), available online (www.ginasthma.org). ICS: inhaled corticosteroids. Figure modified with permission of GINA.

References

    1. To T, Stanojevic S, Moores G, et al. . Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12: 204.
    1. Lai CKW, Beasley R, Crane J, et al. . Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009; 64: 476–483.
    1. Lozano R, Naghavi M, Foreman K, et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2095–2128.
    1. Vos T, Flaxman AD, Naghavi M, et al. . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–2196.
    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO workshop report. NIH Publication number 95-3659A. 1995. Available from
    1. Demoly P, Paggiaro P, Plaza V, et al. . Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev 2009; 18: 105–112.
    1. Fuhlbrigge A, Reed ML, Stempel DA, et al. . The status of asthma control in the U.S. adult population. Allergy Asthma Proc 2009; 30: 529–533.
    1. Gold LS, Thompson P, Salvi S, et al. . Level of asthma control and health care utilization in Asia-Pacific countries. Respir Med 2014; 108: 271–277.
    1. Wisnivesky JP, Lorenzo J, Lyn-Cook R, et al. . Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol 2008; 101: 264–270.
    1. Partridge MR. Translating research into practice: how are guidelines implemented? Eur Respir J 2003; 21: Suppl. 39, 23s–29s.
    1. Baiardini I, Braido F, Bonini M, et al. . Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol 2009; 9: 228–233.
    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2006. Available from:
    1. Roche N, Reddel HK, Agusti A, et al. . Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013; 1: e29–e30.
    1. Boulet LP, FitzGerald JM, Levy ML, et al. . A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J 2012; 39: 1220–1229.
    1. Aaron SD, Vandemheen KL, Boulet LP, et al. . Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J 2008; 179: 1121–1131.
    1. Lucas AEM, Smeenk FWJM, Smeele IJ, et al. . Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract 2008; 25: 86–91.
    1. Marklund B, Tunsäter A, Bengtsson C. How often is the diagnosis bronchial asthma correct? Fam Pract 1999; 16: 112–116.
    1. Montnémery P, Hansson L, Lanke J, et al. . Accuracy of a first diagnosis of asthma in primary health care. Fam Pract 2002; 19: 365–368.
    1. FitzGerald JM, Poureslami I. The need for humanomics in the era of genomics and the challenge of chronic disease management. Chest 2014; 146: 10–12.
    1. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107–1119.
    1. Reddel HK, Taylor DR, Bateman ED, et al. . An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
    1. Wechsler ME, Kelley JM, Boyd IOE, et al. . Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119–126.
    1. Lazarus SC, Boushey HA, Fahy JV, et al. . Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583–2593.
    1. Jenkins CR, Thien FCK, Wheatley JR, et al. . Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 2005; 26: 36–44.
    1. Bateman ED, Reddel HK, Eriksson G, et al. . Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600–608.
    1. Pavord ID, Korn S, Howarth P, et al. . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659.
    1. Haldar P, Pavord ID, Shaw DE, et al. . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–224.
    1. Pellegrino R, Viegi G, Brusasco V, et al. . Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948–968.
    1. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. . FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107: 61–67.
    1. Osborne ML, Pedula KL, O'Hollaren M, et al. . Assessing future need for acute care in adult asthmatics: the profile of asthma risk study: a prospective health maintenance organization-based study. Chest 2007; 132: 1151–1161.
    1. Moore V, Jaakkola M, Burge S. A systematic review of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Eur Respir J 2011; 38: Suppl. 55, P4941.
    1. Jansen J, McCaffery KJ, Hayen A, et al. . Impact of graphic format on perception of change in biological data: implications for health monitoring in conditions such as asthma. Prim Care Respir J 2012; 21: 94–100.
    1. Chung KF, Wenzel SE, Brozek JL, et al. . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
    1. Bel EH, Sousa A, Fleming L, et al. . Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910–917.
    1. Melani AS, Bonavia M, Cilenti V, et al. . Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938.
    1. Boulet LP, Vervloet D, Magar Y, et al. . Adherence: the goal to control asthma. Clin Chest Med 2012; 33: 405–417.
    1. Armour CL, Reddel HK, LeMay KS, et al. . Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomized trial. J Asthma 2013; 50: 302–309.
    1. Schatz M, Sorkness CA, Li JT, et al. . Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117: 549–556.
    1. Juniper EF, O'Byrne PM, Guyatt GH, et al. . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902–907.
    1. Vignola AM, Chanez P, Campbell AM, et al. . Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403–409.
    1. Suissa S, Ernst P, Benayoun S, et al. . Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
    1. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880–884.
    1. Pauwels RA, Pedersen S, Busse WW, et al. . Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071–1076.
    1. Boulet LP, Turcotte H, Prince P, et al. . Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Respir Med 2009; 103: 1554–1563.
    1. Reddel HK, Belousova EG, Marks GB, et al. . Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Prim Care Respir J 2008; 17: 39–45.
    1. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005; 50: 1360–1374.
    1. Basheti IA, Reddel HK, Armour CL, et al. . Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol 2007; 119: 1537–1538.
    1. Wilson SR, Strub P, Buist AS, et al. . Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566–577.
    1. Rosas-Salazar C, Apter AJ, Canino G, et al. . Health literacy and asthma. J Allergy Clin Immunol 2012; 129: 935–942.
    1. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group. Respiration 1998; 65: 195–198.
    1. Basheti IA, Qunaibi E, Bosnic-Anticevich SZ, et al. . User error with Diskus and Turbuhaler by asthma patients and pharmacists in Jordan and Australia. Respir Care 2011; 56: 1916–1923.
    1. Borrelli B, Riekert KA, Weinstein A, et al. . Brief motivational interviewing as a clinical strategy to promote asthma medication adherence. J Allergy Clin Immunol 2007; 120: 1023–1030.
    1. Foster JM, Smith L, Bosnic-Anticevich SZ, et al. . Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. Intern Med J 2012; 42: e136–144.
    1. Blaiss MS, Nathan RA, Stoloff SW, et al. . Patient and physician asthma deterioration terminology: results from the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012; 33: 47–53.
    1. Royal College of Physicians. Why Asthma Still Kills. The National Review of Asthma Deaths (NRAD). Confidential Enquiry Report. RCP, London, 2014.
    1. FitzGerald JM, Becker A, Sears MR, et al. . Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550–556.
    1. Harrison TW, Oborne J, Newton S, et al. . Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271–275.
    1. Rice-McDonald G, Bowler S, Staines G, et al. . Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 2005; 35: 693–698.
    1. Quon BS, Fitzgerald JM, Lemiere C, et al. . Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 10: CD007524.
    1. Jayaram L, Pizzichini MM, Cook RJ, et al. . Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483–494.
    1. Message SD, Laza-Stanca V, Mallia P, et al. . Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008; 105: 13562–13567.
    1. Gibson PG, Powell H, Coughlan J, et al. . Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; CD001117.
    1. Gibson PG. Asthma action plans: use it or lose it. Prim Care Respir J 2004; 13: 17–18.
    1. Oborne J, Mortimer K, Hubbard RB, et al. . Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180: 598–602.
    1. Canonica GW, Castellani P, Cazzola M, et al. . Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther 2004; 17: 239–247.
    1. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 4: CD007313.
    1. Patel M, Pilcher J, Pritchard A, et al. . Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32–42.
    1. Papi A, Corradi M, Pigeon-Francisco C, et al. . Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 23–31.
    1. Williams LK, Peterson EL, Wells K, et al. . Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128: 1185–1191.e1182.
    1. Spahn J, Sheth K, Yeh WS, et al. . Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. J Allergy Clin Immunol 2009; 124: 1197–1203.
    1. Haughney J, Barnes G, Partridge M, et al. . The Living & Breathing Study: a study of patients’ views of asthma and its treatment. Prim Care Respir J 2004; 13: 28–35.
    1. Janson S, Becker G. Reasons for delay in seeking treatment for acute asthma: the patient's perspective. J Asthma 1998; 35: 427–435.
    1. Perrin K, Wijesinghe M, Healy B, et al. . Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax 2011; 66: 937–941.
    1. Rodrigo GJ, Rodriquez Verde M, Peregalli V, et al. . Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003; 124: 1312–1317.
    1. Rowe BH, Spooner CH, Ducharme FM, et al. . Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007; 3: CD000195.
    1. Miller MK, Lee JH, Miller DP, et al. . Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007; 101: 481–489.
    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Revised 2014 Vancouver, GINA, 2014. Available from:
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2015. Available from:
    1. Kauppi P, Kupiainen H, Lindqvist A, et al. . Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011; 48: 279–285.
    1. Marsh SE, Travers J, Weatherall M, et al. . Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761–767.
    1. Weatherall M, Travers J, Shirtcliffe PM, et al. . Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812–818.
    1. Cates CJ, Wieland LS, Oleszczuk M, et al. . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 2: CD010314.
    1. Nannini LJ, Poole P, Milan SJ, et al. . Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 8: CD006826.
    1. Herland K, Akselsen JP, Skjønsberg OH, et al. . How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005; 99: 11–19.
    1. Andersen H, Lampela P, Nevanlinna A, et al. . High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J 2013; 7: 342–346.
    1. Levy ML, Fletcher M, Price DB, et al. . International Primary Care Respiratory Group (IPCRG) Guidelines: Diagnosis of respiratory diseases in primary care. Prim Care Respir J 2006; 15: 20–34.
    1. van Schayck CP, Levy ML, Chen JC, et al. . Coordinated diagnostic approach for adult obstructive lung disease in primary care. Prim Care Respir J 2004; 13: 218–221.
    1. English RG, Bachmann MO, Bateman ED, et al. . Diagnostic accuracy of an integrated respiratory guideline in identifying patients with respiratory symptoms requiring screening for pulmonary tuberculosis: a cross-sectional study. BMC Pulm Med 2006; 6: 22.
    1. Roberts NJ, Smith SF, Partridge MR. Why is spirometry underused in the diagnosis of the breathless patient: a qualitative study. BMC Pulm Med 2011; 11: 37.
    1. Pedersen SE, Hurd SS, Lemanske RF Jr, et al. . Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol 2011; 46: 1–17.
    1. Brand PL, Baraldi E, Bisgaard H, et al. . Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096–1110.
    1. Martinez FD, Wright AL, Taussig LM, et al. . Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133–138.
    1. Henderson J, Granell R, Heron J, et al. . Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. Thorax 2008; 63: 974–980.
    1. Savenije OE, Kerkhof M, Koppelman GH, et al. . Predicting who will have asthma at school age among preschool children. J Allergy Clin Immunol 2012; 130: 325–331.
    1. Schultz A, Devadason SG, Savenije OE, et al. . The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr 2010; 99: 56–60.
    1. Spycher BD, Silverman M, Brooke AM, et al. . Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. Eur Respir J 2008; 31: 974–981.
    1. Brand PL, Caudri D, Eber E, et al. . Classification and pharmacological treatment of preschool wheezing: changes since 2008. Eur Respir J 2014; 43: 1172–1177.
    1. Sly PD, Boner AL, Bjorksten B, et al. . Early identification of atopy in the prediction of persistent asthma in children. Lancet 2008; 372: 1100–1106.
    1. Castro-Rodriguez JA, Holberg CJ, Wright AL, et al. . A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162: 1403–1406.
    1. Van Der Heijden HH, Brouwer ML, Hoekstra F, et al. . Reference values of exhaled nitric oxide in healthy children 1–5 years using off-line tidal breathing. Pediatr Pulmonol 2014; 49: 291–295.
    1. Singer F, Luchsinger I, Inci D, et al. . Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy 2013; 68: 531–538.
    1. O'Byrne PM, Pedersen S, Schatz M, et al. . The poorly explored impact of uncontrolled asthma. Chest 2013; 143: 511–523.
    1. Papi A, Nicolini G, Baraldi E, et al. . Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009; 64: 1463–1471.
    1. Zeiger RS, Mauger D, Bacharier LB, et al. . Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365: 1990–2001.
    1. Bacharier LB, Phillips BR, Zeiger RS, et al. . Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122: 1127–1135 e1128.
    1. Robertson CF, Price D, Henry R, et al. . Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175: 323–329.
    1. Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med 1994; 23: 1236–1241.
    1. Powell C, Kolamunnage-Dona R, Lowe J, et al. . Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med 2013; 1: 301–308.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir